We recently published 7 Best ASX Stocks to Buy Right Now.  Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks. Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure, and other ailments. On November 25th, Jefferies upgraded the firm’s shares to Buy from Hold and increased the share price target to AUD3.30 from AUD3.00. The financial firm cited Mesoblast Limited (NASDAQ:MESO)’s Ryoncil drug as the reason behind its optimism. Jeff ...

Key Takeaways RCUS fell 14.4% after discontinuing the phase III STAR-221 study in upper GI cancers following OS data.The domvanalimab combo failed to beat nivolumab plus chemo on survival, though safety was comparable.RCUS will pivot focus to casdatifan and other oncology and I&I programs, with cash funding into 2028.Shares of Arcus Biosciences, Inc. (RCUS) , a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility ...

Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal vaccine candidate known as VXV‑01, which was developed using a proprietary TLI vaccine technology platform, is poised to move forward in development up to and including Phase 1 clinical evaluation — enabled by a major contract awarded to a collaboration  consortium of Vitalex and Appili Therapeutics (TSX: APLI; OTCPi ...

Three storm-lit steel safes sit in the rain with glowing stacks of cash at their base. Key Points Capital returns in the form of share buybacks and dividend payments are an attractive element for many investors, helping to boost value in ways other than through share price growth. In the current environment, companies able to provide solid cash flow for these returns are increasingly rare. Three names to keep an eye on for their cash flow and returns include Gilead Sciences, Applied Materials, and Qual ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased securities during the specified class period, alleging misleading statements regarding the company's business and operations [1][3]. Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [2]. Allegations - The lawsuit claims that the defendants made false or misleading statements, including: - Materially overstated progress on prostate cancer therapeutic candidates [3]. - Exaggerated quality and performance of the company's supply chain and partners [3]. - Resulting statements about the company's business, operations, and prospects were allegedly false or lacked a reasonable basis [3]. Investor Information - Investors who purchased Telix securities during the class period have until January 9, 2026, to seek appointment as lead plaintiff representative [2].

Core Insights - Actuate Therapeutics, Inc. announced promising results from a Phase II study of elraglusib, showing a median overall survival of 18.6 months and 40% of patients alive at 2 years [1][5][6] Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with elraglusib as its lead investigational drug targeting GSK-3β [8] Study Details - The Phase II study evaluated elraglusib in combination with platinum chemotherapy in patients with advanced, metastatic salivary gland cancers, including adenoid cystic carcinoma [3][7] - The study enrolled 32 patients, with a median progression-free survival of 6.4 months and 27% of patients progression-free at 1 year [5][11] Key Findings - Nuclear GSK-3β expression was significantly higher in responders (50%) compared to non-responders (2%), suggesting its potential as a biomarker for treatment response [3][11] - Among non-ACC patients receiving immune priming followed by cisplatin plus elraglusib, the response rate was 18%, with all responders showing elevated nuclear GSK-3β expression [4][6] Treatment Efficacy - The median overall survival for non-ACC patients was notably higher at 27.8 months, indicating a potential benefit of elraglusib in this subgroup [5] - The combination treatment was well tolerated, with no treatment-related deaths and a low discontinuation rate due to toxicity [11]

37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share capital) were a ...

With a market cap of $18.7 billion, Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. Its marketed portfolio includes treatments for oncology, hematology, and immune-related diseases. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Incyte fits this criterion perfectly. The company also adv ...

Under the terms of the agreement, Dren Bio will receive an upfront payment of $100 million and is eligible to receive up to $1.7 billion in development, regulatory, and commercial milestone payments. The companies will collaborate on discovery and preclinical development activities leveraging Dren Bio's proprietary platform. Following development candidate selection, Sanofi will assume subsequent responsibility for development, manufacturing, regulatory, and commercialization efforts. Dren Bio has the optio ...

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January ...